Top-News

Vical News

Keine aktuellen Kursdaten verfügbar
WKN: A2AKQ5
ISIN: US9256022032
US-Symbol: VICL
Typ: Aktie

Vical News

08.08.19 - PR Newswire
Moore Kuehn, PLLC Encourages Vical Incorporated (VICL), ASV Holdings, Inc. (ASV), PCM, Inc. (PCMI), WageWorks, Inc. (WAGE), and Acacia Communications, Inc. (ACIA) Investors to Contact Firm
Moore Kuehn, PLLC Encourages Vical Incorporated (VICL), ASV Holdings, Inc. (ASV), PCM, Inc. (PCMI), WageWorks, Inc. (WAGE), and Acacia Communications, Inc. (ACIA) Investors ...
12.06.19 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition
SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition PR Newswire
29.01.18 - PR Newswire
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group PR Newswire
22.01.18 - PR Newswire
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients PR Newswire
10.12.13 - PR Newswire
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients PR Newswire
14.11.13 - PR Newswire
Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action
Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action PR Newswire
07.11.13 - PR Newswire
Harwood Feffer LLP Announces Investigation of Vical Incorporated
Harwood Feffer LLP Announces Investigation of Vical Incorporated PR Newswire
12.08.13 - PR Newswire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated PR Newswire
21.09.12 - Aktiencheck
Vical-Aktie: "buy" - Canaccord Genuity
Die Analysten von Canaccord Genuity stufen die Vical-​Aktie in einer Ersteinschätzung mit dem Rating "buy" ein. Das Kursziel werde bei 7,00 USD gesehen. (Analyse vom ...
14.02.11 - aktiencheck
Vical: Prüfungskomitee empfiehlt Fortsetzung der klinischen Studie mit Allovectin-7
30.08.10 - Aktiencheck
Vical könnte zum echten Homerun werden - Global Biotech Investing
Die Experten von "Global Biotech Investing" empfehlen Anlegern bei der Aktie von Vical erste Positionen aufzubauen. Das Biotech-​Unternehmen Vical sei im Bereich neuer ...
03.03.04 - Aktiencheck
Vical für Spekulative - Biotech-Report
06.08.03 - Aktiencheck
Vical abwarten - Der Aktionär
10.07.03 - Aktiencheck
Vical spekulativer Kauf - FOCUS-MONEY
01.07.03 - Aktiencheck
Vical engagiert bleiben - Der Aktionär
22.04.02 - Aktiencheck
Vical Incorporated kaufen - Biotech-Report
05.06.01 - Aktiencheck
Vical spekulativ kaufen - Der Aktionär-online
17.05.01 - Aktiencheck
Vical kaufen - Biotech-Report Online
22.02.01 - Aktiencheck
Vical kaufen - Die Telebörse
13.03.00 - Aktiencheck
VICAL Kursziel 150 $ - Global Biotech Investing

Newssuche

Videos

newspaper
09:30 Uhr +26,02%
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »